['ulcerative colitis']
['etrasimod', 'placebo']

        Inclusion Criteria:

          -  Moderately to severely active ulcerative colitis defined as a 3-component Mayo Clinic
             score

          -  Evidence of colonic ulcerative colitis activity on endoscopy

        Exclusion Criteria:

          -  Within 30 days prior to randomization, receipt of any of the following for the
             treatment of underlying disease: Non-biologic therapies (eg, cyclosporine, tacrolimus,
             tofacitinib, thalidomide), a non-biologic investigational therapy or an approved
             non-biologic therapy in an investigational protocol

          -  Within 60 days prior to randomization, receipt of any of the following: Infliximab,
             adalimumab, golimumab, certolizumab or any other investigational or approved biologic
             agent

          -  Any prior exposure to natalizumab, efalizumab, or rituximab
      